Pfizer (PFE) Goodwill & Intangibles (2009 - 2026)

Pfizer has disclosed Goodwill & Intangibles across 18 years of filings, most recently posting $124.0 billion for Q1 2026.

• In Q1 2026, Goodwill & Intangibles rose 1.26% year-over-year to $124.0 billion; the TTM figure through Mar 2026 stood at $124.0 billion (up 1.26% YoY), while the FY2025 annual figure was $125.0 billion, up 0.85% from the prior year.
• Goodwill & Intangibles eased to $124.0 billion in Q1 2026, from $125.0 billion in the prior quarter.
• Over the last five years, Goodwill & Intangibles for PFE reached as high as $132.7 billion in Q4 2023 and fell as low as $77.6 billion in Q4 2022.
• The 5-year median for Goodwill & Intangibles is $121.7 billion (2025), against an average of $110.0 billion.
• Annual changes were most pronounced in 2024 — Goodwill & Intangibles surged 41.34% — and 2025, when it dropped 7.35%.
• A 5-year view of Goodwill & Intangibles shows it stood at $94.7 billion in 2022, then jumped by 40.04% to $132.7 billion in 2023, then declined by 6.59% to $123.9 billion in 2024, then advanced by 0.85% to $125.0 billion in 2025, then slipped by 0.82% to $124.0 billion in 2026.
• According to Business Quant data, Goodwill & Intangibles over the past three periods registered $124.0 billion, $125.0 billion, and $120.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.